Endotoxin and nanobacteria in polycystic kidney disease

Kidney International

Volumn 57, Issue 6, 2000, Pages 2360-2374

  Hjelle, J Thomas ^a,b,c   Miller Hjelle, Marcia A ^a,b,c   Poxton, Ian R ^a,b,c   Kajander, E Olavi ^a,b,c   Ciftcioglu, Neva ^a,b,c   Jones, Monica L ^a,b,c   Caughey, Robert C ^a,b,c   Brown, Robert ^a,b,c   Millikin, Paul D ^a,b,c   Darras, Frank S ^a,b,c  

^a ILLINOIS COLLEGE   (United States)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Bacteroides; Bartonella; Chlamydia; Citrate; Liver cysts; Simple cystic disease; Tetracycline

Indexed keywords

BACTERIAL ANTIGEN; BACTERIUM LIPOPOLYSACCHARIDE; CITRIC ACID; ENDOTOXIN; HYPERIMMUNE GLOBULIN; MONOCLONAL ANTIBODY; TETRACYCLINE;

ADULT; ARTICLE; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; BACTEROIDES FRAGILIS; BARTONELLA HENSELAE; CHLAMYDIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYST FLUID; ESCHERICHIA COLI; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY POLYCYSTIC DISEASE; LIMULUS LYSATE TEST; LIVER CYST; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY;

EID: 0034076517     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2000.00096.x     Document Type: Article

References (49)

1. 1. CASSELL GH: Infectious causes of chronic inflammatory diseases and cancer. Emerg Infect Dis 4:475-487, 1998
2. 2. GABOW PA, JOHNSON AM, KAEHNY WD, KIMBERLING WJ, LEZOTTE DC, DULEY IT, JONES RH: Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Kidney Int 41:1311-1319, 1992
3. 3. WERDER AA, AMOS MA, NIELSEN AH, WOLFF GH: Comparative effects of germ free and ambient environments on the development of cystic kidney disease in CFW wd mice. J Lab Clin Med 103:399-407, 1984
4. 4. GARDNER KD JR, EVAN AP, REED WP: Accelerated renal cyst development in deconditioned germ free rats. Kidney Int 29:1116-1123, 1986
5. 5. GARDNER KD JR, REED WP, EVAN AP, ZEDALIS J, HYLARIDES MD, LEON AA: Endotoxin provocation of experimental renal cystic disease. Kidney Int 32:329-334, 1987
6. 6. MARTINEZ RR, GRANTHAM JJ: Polycystic kidney disease: Etiology, pathogenesis, and treatment. Dis Mon 41:698-765, 1995
7. 7. QIAN F, WATNICK TJ, ONUCHIC LF, GERMINO GG: The molecular basis of focal cyst formation in human autosomal dominant polycystic kidney disease type 1. Cell 87:979-987, 1996
8. 8. BRASIER JL, HENSKE EP: Loss of the polycystic kidney disease region of chromosome 16P13 in renal cyst cells supports a loss of function model for cyst pathogenesis. J Clin Invest 99:194-199, 1997
9. 9. MILLER-HJELLE MA, HJELLE JT, JONFS M, MAYBERRY WR, DOMBRINK-KURTZMAN MA, PETERSON SW, NOWAK DM, DARRAS FS: Polycystic kidney disease: An unrecognized emerging infectious disease? Emerg Infect Dis 3:113-127, 1997
10. 10. TORRES VE: New insights into polycystic kidney disease and its treatment. Curr Opin Nephrol Hypertens 7:159-169, 1998
11. 11. CALVET JP: Molecular genetics of polycystic kidney disease. J Nephrol 11:24-34, 1998
12. 12. SCHWAB S, BANDER S, SAULO K: Renal infection in autosomal dominant polycystic kidney disease. Am J Med 82:714-718, 1987
13. 13. SKLAR A, CARUANA RJ, LAMMERS JE, STRAUSER GD: Renal infection in autosomal dominant polycystic kidney disease. Am J Kidney Dis 10:81-88, 1987
14. 14. ROSCOE JM, BRISSENDEN JE, WILLIAMS EA, CHERY AL, SILVERMAN M: Autosomal dominant polycystic kidney disease in Toronto. Kidney Int 44:1101-1108, 1993
15. 15. BJARNASON I, MACPHERSON A, HOLLANDER D: Intestinal permeability: An overview. Gastroenterology 108:1566-1581, 1995
16. 16. SCHEFF RT, ZUCKERMAN G, HARTER H, DELMEZ J, KOEHLER R: Diverticular disease in individuals with chronic renal failure due to polycystic kidney disease. Ann Intern Med 92:202-204, 1980
17. 17. MILLER MA, PRIOR RB, HORVATH FJ, HJELLE JT: Detection of endotoxiuria in polycystic kidney disease patients by the use of the Limulus Amoebocyte lysate assay. Am J Kidney Dis 15:117-122, 1990
18. 18. GARDNER KD JR, BURNSIDE J, ELZINGA L: Cytokines in fluids from polycystic kidneys. Kidney Int 39:718-724, 1991
19. 19. KAJANDER EO, KURONEN I, AKERMAN K, PELTTARI A, CIFTCIOGLU N: Nanobacteria from blood, the smallest culturable autonomously replicating agent on Earth. Proc SPIE Int Soc Opt Eng 3111:420-428, 1997
20. 20. CIFTCIOGLU N, PELTTARI A, KAJANDER EO: Extraordinary growth phases of nanobacteria isolated from mammalian blood. Proc SPIE Int Soc Opt Eng 3111:429-435, 1997
21. 21. KAJANDER EO, BJORKLUND M, CIFTCIOGLU N: Mineralization by nanobacteria. Proc SPIE Int Soc Opt Eng 3441:86-94, 1998
22. 22. BJORKLUND M, CIFTCIOGLU N, KAJANDER EO: Extraordinary survival of nanobacteria under extreme conditions. Proc SPIE Int Soc Opt Eng 3441:86-94, 1998
23. 23. KAJANDER EO, CIFTCIOGLU N: Nanobacteria: An alternative mechanism for pathogenic intra-and extracellular calcification and stone formation. Proc Natl Acad Sci USA 95:8274-8279, 1998
24. 24. CIFTCIOGLU N, BJORKLUND M, KUORIKOSKI K, BERGSTROM K, KAJANDER EO: Nanobacteria: An infectious cause for kidney stone formation. Kidney Int 56:1893-1898, 1999
25. 25. CIFTCIOGLU N, BJORKLUND M, KAJANDER EO: Stone formation and calcification by nanobacteria in human body. Proc SPIE Int Soc Opt Eng 3441:105-111, 1998
26. 26. CIFTCIOGLU N, KAJANDER EO: Interaction of nanobacteria with cultured mammalian cells. Pathophysiology 4:259-270, 1998
27. 27. AKERMAN KK, KUIKKA JT, CIFTCIOGLU N, PARKKINEN J, BERGSTROM KA, KURONEN I, KAJANDER EO: Radiolabeling and in vivo distribution of nanobacteria in rabbit. Proc SPIE Int Soc Opt Eng 3111:436-442, 1997
28. 28. Woo D: Apoptosis and loss of renal tissue in polycystic kidney disease. N Engl J Med 333:18-25, 1995
29. 29. LANOIX J, D'AGATI V, SZABOLCS M, TRUDEL M: Dysregulation of cellular proliferation and apoptosis mediates human autosomal dominant polycystic kidney disease. Oncogene 13:1153-1160, 1996
30. 30. TORRES VE, WILSON DM, HATTERY RR, SEGURA JW: Renal stone disease in autosomal dominant polycystic kidney disease. Am J Kidney Dis 22:513-519, 1993
31. 31. TANNER GA, GRETZ N, CONNORS BA, EVAN AP, SIEINHAUSEN M: Role of obstruction in autosomal dominant polycystic kidney disease in rats. Kidney Int 50:424-431, 1996
32. 32. PLOEG RJ, VAN BOCKEL JH, LANGENDUK PT, GROENEWEGEN M, VAN DER WOUDE FJ, PERSIJN GG, THOROGOOD J, HERMANS J: Effect of preservation solution on results of cadaveric kidney transplantation: The European Multicentre Study Group. Lancet 340:129-137, 1992
33. 33. POXTON IR, MYERS CJ, JOHNSTONE A, DRUDY TA, FERGUSON A: An ELISA to measure mucosal IgA specific for Bacteroides surface antigens in whole gut lavage fluid. Microb Ecol Health Dis 8:129-136, 1995
34. 34. GIBB AP, BARCLAY GR, POXION IR, DI PADOVA F: Frequencies of lipopolysaccharide core types among clinical isolates of Escherichia coli defined with monoclonal antibodies. J Infect Dis 166:1051-1057, 1992
35. 35. KAREM KL, DUBOIS K, MCGILL S, REGNERY R: Characterization of Bartonella henselae specific immunity in BALB/C mice. Immunology 97:352-358, 1999
36. 36. POXTON IR, BROWN R, SAWYERR A, FERGUSON A: Mucosa-associated bacterial flora of the human colon. J Med Microbiol 46:85-91, 1977
37. 37. HJELLE JT, WATERS DC, GOLINSKA BT, SIEIDLEY KR, BURMEISTER V, CAUGHEY R, KETEL B, MCCARROLL DR, OLSSON PJ, PRIOR RB, MILLER MA: Autosomal recessive polycystic kidney disease: Characterization of human peritoneal and cystic kidney cells in vitro. Am J Kidney Dis 15:123-136, 1990
38. 38. TANNER GA: Potassium citrate/citric acid intake improves renal function in rats with polycystic kidney disease. J Am Soc Nephrol 9:1242-1248, 1998
39. 39. SCHEID C, KOUI H, HILL WA, LUBER-NAROD J, KINNINGTON L, HONEYMAN T, JONASSEN J, MENON M: Oxalate toxicity in LLC-PK1 cells: Role of free radicals. Kidney Int 49:413-419, 1996
40. 40. KALAYOGLU MV, BYRNE GI: A Chlamydia pneumoniae component that induces macrophage foam cell formation is chlamydial lipopolysaccharide. Infect Immunol 66:5067-5072, 1998
41. 41. MAURIN M, EB R, ETIENNE J, RAOULT D: Serological cross-reactions between Bartonella and Chlamydia species: Implications for diagnosis. J Clin Microbiol 35:2283-2287, 1997
42. 42. KOEHLER JE, SANCHEZ MA, BARRIDO CS, WHITFIELD MJ, CHEN FM, BERGER TG, RODRIGUEZ-BARRADAS MC, LEBOTI PE, TAPPERO JW: Molecular epidemiology of Bartonella infections in patients with bacillary angiomatosis-peliosis. N Engl J Med 337:1876-1883, 1997
43. 43. SPACH DH, KOEHLER J: Bartonella-associated infections. Infect Dis Clin North Am 12:137-155, 1998
44. 44. STENVINKEL P, HEIMBURGER O, JOGESTRAND T, KARNELL A, SAMUELSSON A: Does persistent infection with Chlamyilia pneumoniae increase the risk of atherosclerosis in chronic renal failure? Kidney Int 55:2531-2532, 1999
45. 45. CARSON DA: An infectious origin of extraskeletal calcification. Proc Natl Acad Sci USA 95:7846-7847, 1998
46. 46. CALVET JP: Injury and development in polycystic kidney disease. Curr Opin Nephrol Hypertens 3:340-348, 1994
47. 47. MANDEL N: Mechanism of stone formation. Semin Nephrol 16:364-374, 1996
48. 48. OGBURN MR, NITSCHMANN E, BANKOVIC-CALIC N, BUIST R, PEELING J: The effect of dietary flaxseed supplementation on organic anion and osmolyte content and excretion in rat polycystic kidney disease. Biochem Cell Biol 76:553-559, 1998
49. 49. GILE RD, COWLEY BD JR, GATTONE VH II, O'DONNELL MP, SWAN SK, GRANTHAM JJ: Effect of lovastatin on the development of polycystic kidney disease in the Han:SPRD rat. Am J Kidney Dis 26:501-407, 1995